The Growing Power of Biotech Monopolies Threatens Affordable Care
Share
The U.S. has worsened the problem by making the 12-year auto-monopoly a key sticking point in its trade negotiations with the Pacific Rim and with Canada and Mexico: demanding that other countries also adopt the same rule, regardless of underlying intellectual property. Those who favor an innovative pharmceutical market should oppose mandatory monopolies for which innovation is absent.Featured Publications
How Trump’s “10-to-1” Deregulation Initiative Is Taking Shape in Financial Services
Safer Solutions: Why Focusing Exclusively On Drug Supply Isn’t Enough
Prosecutors' Case for Survivor Sentencing Laws
High-Impact Legislative Recommendations for Florida Insurance Reform
ROFR in Retreat